Posted by Michael Wonder on 05 Jun 2018
GSK meets South Australian politicians to push meningococcal vaccine program
5 June 2018 - GSK’s head of global vaccines met South Australian officials yesterday in an attempt to win support for a government-funded program for the pharmaceutical giant’s meningococcal B vaccine.
Luc Debruyne, president of global vaccines at GSK, told The Australian before the meetings that investing in prevention was the best intervention for healthcare.
The meningococcal B vaccine, known as Bexsero, costs Australians about $120 because it is not available as part of the Australian government’s national immunisation program.
